Here's a closer look at why Houston should be pushing for a more rapid transition to EVs. Photo via Getty Images

As urban populations increase and more vehicles hit the roads across the United States, the quality of the air is compromised, directly impacting health, environment, and quality of life ― especially for children, minorities, and other vulnerable populations. A 2023 study by Site Selection Group placed Houston at the vanguard of this trend, projecting the metro area to grow nearly 10 percent by 2028, eclipsing 8 million residents.

According to Evolve Houston, a nonprofit working to accelerate EV adoption by bringing together local public and private organizations, residents, and government, the transportation sector emits 47 percent of all greenhouse gas emissions in the Houston area.

In this context, electric vehicles offer a practical solution to mitigate the challenges posed by tailpipe emissions. Their adoption in urban settings has the potential to significantly improve air quality and enhance public health. It’s no wonder the upcoming Houston Auto Show will feature a dedicated EV Pavilion.

Here's a closer look at why Houston should be pushing for a more rapid transition to EVs:

  1. Children’s development is at stake: Early childhood is a critical period for brain development. However, toxic air pollutants can significantly inhibit this growth during these formative years. The consequences include impairing children’s cognitive capabilities in reading and math, akin to missing an entire month of elementary school.
  2. EVs counteract historical racial inequalities: Beyond being an environmental challenge, air pollution is a glaring racial and social justice issue. Areas with fewer White residents suffer almost triple the nitrogen dioxide levels compared to predominantly White zones, as highlighted by the National Academy of Sciences. Historically marginalized communities, often near major traffic corridors, endure heightened pollution exposure. Transitioning to EVs can help address these deeply ingrained environmental inequities.
  3. The health benefits are monumental: A brighter future awaits if EVs become mainstream. According to the American Lung Association, if all new vehicles sold by 2035 are zero-emission, the U.S. could see up to 89,300 fewer premature deaths by 2050. Additionally, asthma attacks might decline by 2 million, saving 10.7 million workdays and resulting in an incredible $978 billion in public health savings.
  4. Global success stories prove the benefits: The impact of mass EV adoption has already been demonstrated outside the U.S. For instance, Norway has seen a notable reduction in dangerous particle emissions since 87 percent of its new car sales are now fully electric. Likewise, California’s adoption of electric vehicles correlated with a 3.2% decrease in asthma-related ER visits between 2013 and 2019.
  5. Cities have the power and means to lead the way: Many global cities are trailblazers in the electric transition. New York City, with more than 4,000 government-owned EVs, is a prime example. Moreover, by electrifying their take-home fleets, cities can set a precedent for their communities. Seeing neighbors drive electric vehicles daily serves as a powerful endorsement, motivating nearby residents to make the switch. Incentives like public charging stations, free parking for EVs, rebates for home charger installations, reimbursing for charging at home, and reduced tolls, further bolster this movement.

Houstonians stand at a pivotal juncture. The choices made today concerning transportation will profoundly influence the health and well-being of residents tomorrow. The shift to electric vehicles is more than just an eco-friendly choice; it's a commitment to a brighter, cleaner future. By leading with action and vision, cities can create a legacy that upcoming generations will appreciate and thrive in.

------

Kate L. Harrison is the co-founder and head of marketing at MoveEV, an AI-backed EV transition company that helps organizations convert fleet and employee-owned gas vehicles to electric, and reimburse for charging at home.

This article originally ran on EnergyCapital.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston biotech company tests hard-to-fight cancer therapeutics

fighting cancer

A Houston-based, female-founded biotech company has developed a treatment that could prove to be an effective therapy for a rare blood cancer.

Cellenkos Therapeutics has completed promising Phase 1b testing of its Treg cell therapy, CK0804, in the fight against myelofibrosis. According to a news release from the Cellenkos team, the use of its cord-blood-derived therapeutics could signal a paradigm shift for the treatment of this hard-to-fight cancer.

Cellenkos was founded by MD Anderson Cancer Center physician and professor Simrit Parmar. Her research at the hospital displayed the ability of a unique subset of T cells’ capability to home in on a patient’s bone marrow, restoring immune balance, and potentially halting disease progression.

Myelofibrosis has long been treated primarily with JAK (Janus Kinase) inhibitors, medications that help to block inflammatory enzymes. They work by suppressing the immune response to the blood cancer, but don’t slow the progression of the malady. And they’re not effective for every patient.

“There is a significant need for new therapeutic options for patients living with myelofibrosis who have suboptimal responses to approved JAK inhibitors,” Parmar says. “We are greatly encouraged by the safety profile and early signs of efficacy observed in this patient cohort and look forward to continuing our evaluation of the clinical potential of CK0804 in our planned expansion cohort.”

The expansion cohort is currently enrolling patients with myelofibrosis. What exactly are sufferers dealing with? Myelofibrosis is a chronic disease that causes bone marrow to form scar tissue. This makes it difficult for the body to produce normal blood cells, leaving patients with fatigue, spleen enlargement and night sweats.

Myelofibrosis is rare, with just 16,000 to 18,500 people affected in the United States. But for patients who don’t respond well to JAKs, the prognosis could mean a shorter span than the six-year median survival rate outlined for the disease by Cleveland Clinic.

Helping myelofibrosis patients to thrive isn’t the only goal for Cellenkos right now.

The company seeks to aid people with rare conditions, particularly inflammatory and autoimmune disorders, with the use of CK0804, but also other candidates including one known as CK0801. The latter drug has shown promising efficacy in aplastic anemia, including transfusion independence in treated patients.

The company closed its $15 million series A round led by BVCF Management, based in Shanghai, in 2021. Read more here.

Pioneering Houston biotech startup expands to Brazil for next phase

On the Move

Houston biotech company Cemvita has expanded into Brazil. The company officially established a new subsidiary in the country under the same name.

According to an announcement made earlier this month, the expansion aims to capitalize on Brazil’s progressive regulatory framework, including Brazil’s Fuel of the Future Law, which was enacted in 2024. The company said the expansion also aims to coincide with the 2025 COP30, the UN’s climate change conference, which will be hosted in Brazil in November.

Cemvita utilizes synthetic biology to transform carbon emissions into valuable bio-based chemicals.

“For decades Brazil has pioneered the bioeconomy, and now the time has come to create the future of the circular bioeconomy,” Moji Karimi, CEO of Cemvita, said in a news release. “Our vision is to combine the innovation Cemvita is known for with Brazil’s expertise and resources to create an ecosystem where waste becomes opportunity and sustainability drives growth. By joining forces with Brazilian partners, Cemvita aims to build on Brazil’s storied history in the bioeconomy while laying the groundwork for a circular and sustainable future.”

The Fuel of the Future Law mandates an increase in the biodiesel content of diesel fuel, starting from 15 percent in March and increasing to 20 percent by 2030. It also requires the adoption of Sustainable Aviation Fuel (SAF) and for domestic flights to reduce greenhouse gas emissions by 1 percent starting in 2027, growing to 10 percent reduction by 2037.

Cemvita agreed to a 20-year contract that specified it would supply up to 50 million gallons of SAF annually to United Airlines in 2023.

"This is all made possible by our innovative technology, which transforms carbon waste into value,” Marcio Da Silva, VP of Innovation, said in a news release. “Unlike traditional methods, it requires neither a large land footprint nor clean freshwater, ensuring minimal environmental impact. At the same time, it produces high-value green chemicals—such as sustainable oils and biofuels—without competing with the critical resources needed for food production."

In 2024, Cemvita became capable of generating 500 barrels per day of sustainable oil from carbon waste at its first commercial plant. As a result, Cemvita quadrupled output at its Houston plant. The company had originally planned to reach this milestone in 2029.

---

This story originally appeared on our sister site, EnergyCapitalHTX.